vesnarinone has been researched along with Agranulocytosis in 6 studies
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 9.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Vesnarinone is an important new drug that significantly decreases mortality rates in severe congestive heart failure; however, its use is associated with a relatively high incidence (approximately 1%) of agranulocytosis." | 7.69 | Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. ( Uetrecht, JP; Whitfield, D; Zahid, N, 1994) |
| "Vesnarinone, an oral therapeutic agent for cardiac failure, causes agranulocytosis as a side effect." | 7.69 | Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment. ( Aizawa, S; Handa, H; Hoshi, H; Imai, T; Iwase, O; Kaido, A; Kuriyama, Y; Nabeshima, R; Nakano, M; Sugimoto, K; Tanaka, K; Toyama, K; Yaguchi, M, 1997) |
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 5.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Vesnarinone is an important new drug that significantly decreases mortality rates in severe congestive heart failure; however, its use is associated with a relatively high incidence (approximately 1%) of agranulocytosis." | 3.69 | Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. ( Uetrecht, JP; Whitfield, D; Zahid, N, 1994) |
| "Vesnarinone, an oral therapeutic agent for cardiac failure, causes agranulocytosis as a side effect." | 3.69 | Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment. ( Aizawa, S; Handa, H; Hoshi, H; Imai, T; Iwase, O; Kaido, A; Kuriyama, Y; Nabeshima, R; Nakano, M; Sugimoto, K; Tanaka, K; Toyama, K; Yaguchi, M, 1997) |
| "Vesnarinone (OPC-8212) is a new positive inotropic agent that augments myocardial contractility." | 2.39 | Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. ( Asanoi, H; Furusawa, S; Ohashi, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uetrecht, JP | 1 |
| Zahid, N | 1 |
| Whitfield, D | 1 |
| Saito, K | 1 |
| Waga, K | 1 |
| Yamato, R | 1 |
| Enokihara, H | 1 |
| Furusawa, S | 2 |
| Shishido, H | 1 |
| Hayashida, T | 1 |
| Chen, G | 1 |
| Ohashi, Y | 1 |
| Asanoi, H | 1 |
| Aizawa, S | 1 |
| Nakano, M | 1 |
| Yaguchi, M | 1 |
| Kuriyama, Y | 1 |
| Iwase, O | 1 |
| Toyama, K | 1 |
| Tanaka, K | 1 |
| Hoshi, H | 1 |
| Sugimoto, K | 1 |
| Kaido, A | 1 |
| Imai, T | 1 |
| Nabeshima, R | 1 |
| Handa, H | 1 |
| Cohn, JN | 1 |
| Goldstein, SO | 1 |
| Greenberg, BH | 1 |
| Lorell, BH | 1 |
| Bourge, RC | 1 |
| Jaski, BE | 1 |
| Gottlieb, SO | 1 |
| McGrew, F | 1 |
| DeMets, DL | 1 |
| White, BG | 1 |
1 review available for vesnarinone and Agranulocytosis
| Article | Year |
|---|---|
Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Topics: Adult; Agranulocytosis; Cardiotonic Agents; Humans; Incidence; Japan; Male; Product Surveillance, Po | 1996 |
1 trial available for vesnarinone and Agranulocytosis
| Article | Year |
|---|---|
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Topics: Aged; Agranulocytosis; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Cardiotonic A | 1998 |
4 other studies available for vesnarinone and Agranulocytosis
| Article | Year |
|---|---|
Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.
Topics: Agranulocytosis; Albumins; Cardiotonic Agents; Chromatography, High Pressure Liquid; Glutathione; Hu | 1994 |
Vesnarinone induced agranulocytosis.
Topics: Aged; Agranulocytosis; Bone Marrow; Colony-Forming Units Assay; Female; Humans; Pyrazines; Quinoline | 1993 |
[Suppression of granulopoiesis by vesnarinone].
Topics: Adult; Agranulocytosis; Apoptosis; Cardiotonic Agents; Cells, Cultured; Dose-Response Relationship, | 1996 |
Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell | 1997 |